Developing national treatment policy for falciparum malaria in Africa: Malawi experience
The emergence and spread across sub-Saharan Africa of Plasmodium falciparum resistant to the inexpensive antimalarials chloroquine and sulfadoxine–pyrimethamine has worsened the health and hampered the socio-economic development of affected countries, a situation that calls for urgent review of mala...
Gespeichert in:
| Veröffentlicht in: | Transactions of the Royal Society of Tropical Medicine and Hygiene 2009-04, Vol.103 (1), p.S15-S18 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S18 |
|---|---|
| container_issue | 1 |
| container_start_page | S15 |
| container_title | Transactions of the Royal Society of Tropical Medicine and Hygiene |
| container_volume | 103 |
| creator | Malenga, Grace Wirima, Jack Kazembe, Peter Nyasulu, Yohane Mbvundula, Michael Nyirenda, Cooper Sungani, Francis Campbell, Carl Molyneux, Malcolm Bronzan, Rachel Dodoli, Wilfred Ali, Doreen Kabuluzi, Storn |
| description | The emergence and spread across sub-Saharan Africa of
Plasmodium falciparum resistant to the inexpensive antimalarials chloroquine and sulfadoxine–pyrimethamine has worsened the health and hampered the socio-economic development of affected countries, a situation that calls for urgent review of malaria treatment policies in these countries. The Roll Back Malaria (RBM) initiative promotes strong partnerships for implementing effective malaria control measures. The development of clear policies to guide such implementation at country level offers a way of assessing the achievement of set milestones in this collaborative venture. In this article we describe the policy development process for the treatment of falciparum malaria in Africa, based on experience in Malawi, where the first-line drug treatment was recently changed from sulfadoxine–pyrimethamine to an artemisinin combination therapy. |
| doi_str_mv | 10.1016/j.trstmh.2009.02.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733324382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0035920309000443</els_id><sourcerecordid>733324382</sourcerecordid><originalsourceid>FETCH-LOGICAL-c314t-70f2262b279c904124aaeeb10929551de5ed7de351109e993a30f6a38c40df413</originalsourceid><addsrcrecordid>eNp9kE1P3DAQhi1UBFvKP0CVbz0lHdtxEnOohKCUqou40BZxsbzOpHibr9peCv--plnBjZOl1887M3oIOWKQM2Dlx3UefYj9Xc4BVA48BxA7ZMHqqs6EBPGGLFIiM8VB7JO3IawBuGRS7ZF9pngtS6UW5OYM77EbJzf8ooOJbhxMR6NHE3scIp3GztlH2o6etqazbjJ-09PedMY7Q91AT1rvrDmmlyn66yg-TOgdDhbfkd3UCHi4fQ_I9_PP16cX2fLqy9fTk2VmBStiVkHLeclXvFJWQcF4YQziioHiSkrWoMSmalBIliJUShgBbWlEbQto2oKJA_Jhnjv58c8GQ9S9Cxa7zgw4boKuhBC8EDVPZDGT1o8heGz15F1v_KNmoJ-U6rWeleonpRq4TgJT7f12wWbVY_NS2jpMQDYDLkR8eP43_rcuK1FJfXFzqy_Pb9m3s-UP_TPxn2Yek5Z7h14H-19Z4zzaqJvRvX7RPxUTmVs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733324382</pqid></control><display><type>article</type><title>Developing national treatment policy for falciparum malaria in Africa: Malawi experience</title><source>MEDLINE</source><source>Oxford University Press Journals Current</source><creator>Malenga, Grace ; Wirima, Jack ; Kazembe, Peter ; Nyasulu, Yohane ; Mbvundula, Michael ; Nyirenda, Cooper ; Sungani, Francis ; Campbell, Carl ; Molyneux, Malcolm ; Bronzan, Rachel ; Dodoli, Wilfred ; Ali, Doreen ; Kabuluzi, Storn</creator><creatorcontrib>Malenga, Grace ; Wirima, Jack ; Kazembe, Peter ; Nyasulu, Yohane ; Mbvundula, Michael ; Nyirenda, Cooper ; Sungani, Francis ; Campbell, Carl ; Molyneux, Malcolm ; Bronzan, Rachel ; Dodoli, Wilfred ; Ali, Doreen ; Kabuluzi, Storn</creatorcontrib><description>The emergence and spread across sub-Saharan Africa of
Plasmodium falciparum resistant to the inexpensive antimalarials chloroquine and sulfadoxine–pyrimethamine has worsened the health and hampered the socio-economic development of affected countries, a situation that calls for urgent review of malaria treatment policies in these countries. The Roll Back Malaria (RBM) initiative promotes strong partnerships for implementing effective malaria control measures. The development of clear policies to guide such implementation at country level offers a way of assessing the achievement of set milestones in this collaborative venture. In this article we describe the policy development process for the treatment of falciparum malaria in Africa, based on experience in Malawi, where the first-line drug treatment was recently changed from sulfadoxine–pyrimethamine to an artemisinin combination therapy.</description><identifier>ISSN: 0035-9203</identifier><identifier>EISSN: 1878-3503</identifier><identifier>DOI: 10.1016/j.trstmh.2009.02.003</identifier><identifier>PMID: 19285699</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Africa ; Antimalarials - economics ; Antimalarials - therapeutic use ; Artemisinin ; Artemisinins - economics ; Artemisinins - therapeutic use ; Drug Resistance ; Health Policy - economics ; Humans ; Malaria ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - epidemiology ; Malawi ; Partnerships ; Plasmodium falciparum - drug effects ; Policy making</subject><ispartof>Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009-04, Vol.103 (1), p.S15-S18</ispartof><rights>2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c314t-70f2262b279c904124aaeeb10929551de5ed7de351109e993a30f6a38c40df413</citedby><cites>FETCH-LOGICAL-c314t-70f2262b279c904124aaeeb10929551de5ed7de351109e993a30f6a38c40df413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19285699$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malenga, Grace</creatorcontrib><creatorcontrib>Wirima, Jack</creatorcontrib><creatorcontrib>Kazembe, Peter</creatorcontrib><creatorcontrib>Nyasulu, Yohane</creatorcontrib><creatorcontrib>Mbvundula, Michael</creatorcontrib><creatorcontrib>Nyirenda, Cooper</creatorcontrib><creatorcontrib>Sungani, Francis</creatorcontrib><creatorcontrib>Campbell, Carl</creatorcontrib><creatorcontrib>Molyneux, Malcolm</creatorcontrib><creatorcontrib>Bronzan, Rachel</creatorcontrib><creatorcontrib>Dodoli, Wilfred</creatorcontrib><creatorcontrib>Ali, Doreen</creatorcontrib><creatorcontrib>Kabuluzi, Storn</creatorcontrib><title>Developing national treatment policy for falciparum malaria in Africa: Malawi experience</title><title>Transactions of the Royal Society of Tropical Medicine and Hygiene</title><addtitle>Trans R Soc Trop Med Hyg</addtitle><description>The emergence and spread across sub-Saharan Africa of
Plasmodium falciparum resistant to the inexpensive antimalarials chloroquine and sulfadoxine–pyrimethamine has worsened the health and hampered the socio-economic development of affected countries, a situation that calls for urgent review of malaria treatment policies in these countries. The Roll Back Malaria (RBM) initiative promotes strong partnerships for implementing effective malaria control measures. The development of clear policies to guide such implementation at country level offers a way of assessing the achievement of set milestones in this collaborative venture. In this article we describe the policy development process for the treatment of falciparum malaria in Africa, based on experience in Malawi, where the first-line drug treatment was recently changed from sulfadoxine–pyrimethamine to an artemisinin combination therapy.</description><subject>Africa</subject><subject>Antimalarials - economics</subject><subject>Antimalarials - therapeutic use</subject><subject>Artemisinin</subject><subject>Artemisinins - economics</subject><subject>Artemisinins - therapeutic use</subject><subject>Drug Resistance</subject><subject>Health Policy - economics</subject><subject>Humans</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - epidemiology</subject><subject>Malawi</subject><subject>Partnerships</subject><subject>Plasmodium falciparum - drug effects</subject><subject>Policy making</subject><issn>0035-9203</issn><issn>1878-3503</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1P3DAQhi1UBFvKP0CVbz0lHdtxEnOohKCUqou40BZxsbzOpHibr9peCv--plnBjZOl1887M3oIOWKQM2Dlx3UefYj9Xc4BVA48BxA7ZMHqqs6EBPGGLFIiM8VB7JO3IawBuGRS7ZF9pngtS6UW5OYM77EbJzf8ooOJbhxMR6NHE3scIp3GztlH2o6etqazbjJ-09PedMY7Q91AT1rvrDmmlyn66yg-TOgdDhbfkd3UCHi4fQ_I9_PP16cX2fLqy9fTk2VmBStiVkHLeclXvFJWQcF4YQziioHiSkrWoMSmalBIliJUShgBbWlEbQto2oKJA_Jhnjv58c8GQ9S9Cxa7zgw4boKuhBC8EDVPZDGT1o8heGz15F1v_KNmoJ-U6rWeleonpRq4TgJT7f12wWbVY_NS2jpMQDYDLkR8eP43_rcuK1FJfXFzqy_Pb9m3s-UP_TPxn2Yek5Z7h14H-19Z4zzaqJvRvX7RPxUTmVs</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Malenga, Grace</creator><creator>Wirima, Jack</creator><creator>Kazembe, Peter</creator><creator>Nyasulu, Yohane</creator><creator>Mbvundula, Michael</creator><creator>Nyirenda, Cooper</creator><creator>Sungani, Francis</creator><creator>Campbell, Carl</creator><creator>Molyneux, Malcolm</creator><creator>Bronzan, Rachel</creator><creator>Dodoli, Wilfred</creator><creator>Ali, Doreen</creator><creator>Kabuluzi, Storn</creator><general>Elsevier Ltd</general><general>Royal Society of Tropical Medicine and Hygiene</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200904</creationdate><title>Developing national treatment policy for falciparum malaria in Africa: Malawi experience</title><author>Malenga, Grace ; Wirima, Jack ; Kazembe, Peter ; Nyasulu, Yohane ; Mbvundula, Michael ; Nyirenda, Cooper ; Sungani, Francis ; Campbell, Carl ; Molyneux, Malcolm ; Bronzan, Rachel ; Dodoli, Wilfred ; Ali, Doreen ; Kabuluzi, Storn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c314t-70f2262b279c904124aaeeb10929551de5ed7de351109e993a30f6a38c40df413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Africa</topic><topic>Antimalarials - economics</topic><topic>Antimalarials - therapeutic use</topic><topic>Artemisinin</topic><topic>Artemisinins - economics</topic><topic>Artemisinins - therapeutic use</topic><topic>Drug Resistance</topic><topic>Health Policy - economics</topic><topic>Humans</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - epidemiology</topic><topic>Malawi</topic><topic>Partnerships</topic><topic>Plasmodium falciparum - drug effects</topic><topic>Policy making</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Malenga, Grace</creatorcontrib><creatorcontrib>Wirima, Jack</creatorcontrib><creatorcontrib>Kazembe, Peter</creatorcontrib><creatorcontrib>Nyasulu, Yohane</creatorcontrib><creatorcontrib>Mbvundula, Michael</creatorcontrib><creatorcontrib>Nyirenda, Cooper</creatorcontrib><creatorcontrib>Sungani, Francis</creatorcontrib><creatorcontrib>Campbell, Carl</creatorcontrib><creatorcontrib>Molyneux, Malcolm</creatorcontrib><creatorcontrib>Bronzan, Rachel</creatorcontrib><creatorcontrib>Dodoli, Wilfred</creatorcontrib><creatorcontrib>Ali, Doreen</creatorcontrib><creatorcontrib>Kabuluzi, Storn</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malenga, Grace</au><au>Wirima, Jack</au><au>Kazembe, Peter</au><au>Nyasulu, Yohane</au><au>Mbvundula, Michael</au><au>Nyirenda, Cooper</au><au>Sungani, Francis</au><au>Campbell, Carl</au><au>Molyneux, Malcolm</au><au>Bronzan, Rachel</au><au>Dodoli, Wilfred</au><au>Ali, Doreen</au><au>Kabuluzi, Storn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Developing national treatment policy for falciparum malaria in Africa: Malawi experience</atitle><jtitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</jtitle><addtitle>Trans R Soc Trop Med Hyg</addtitle><date>2009-04</date><risdate>2009</risdate><volume>103</volume><issue>1</issue><spage>S15</spage><epage>S18</epage><pages>S15-S18</pages><issn>0035-9203</issn><eissn>1878-3503</eissn><abstract>The emergence and spread across sub-Saharan Africa of
Plasmodium falciparum resistant to the inexpensive antimalarials chloroquine and sulfadoxine–pyrimethamine has worsened the health and hampered the socio-economic development of affected countries, a situation that calls for urgent review of malaria treatment policies in these countries. The Roll Back Malaria (RBM) initiative promotes strong partnerships for implementing effective malaria control measures. The development of clear policies to guide such implementation at country level offers a way of assessing the achievement of set milestones in this collaborative venture. In this article we describe the policy development process for the treatment of falciparum malaria in Africa, based on experience in Malawi, where the first-line drug treatment was recently changed from sulfadoxine–pyrimethamine to an artemisinin combination therapy.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>19285699</pmid><doi>10.1016/j.trstmh.2009.02.003</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0035-9203 |
| ispartof | Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009-04, Vol.103 (1), p.S15-S18 |
| issn | 0035-9203 1878-3503 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733324382 |
| source | MEDLINE; Oxford University Press Journals Current |
| subjects | Africa Antimalarials - economics Antimalarials - therapeutic use Artemisinin Artemisinins - economics Artemisinins - therapeutic use Drug Resistance Health Policy - economics Humans Malaria Malaria, Falciparum - drug therapy Malaria, Falciparum - epidemiology Malawi Partnerships Plasmodium falciparum - drug effects Policy making |
| title | Developing national treatment policy for falciparum malaria in Africa: Malawi experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T19%3A34%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Developing%20national%20treatment%20policy%20for%20falciparum%20malaria%20in%20Africa:%20Malawi%20experience&rft.jtitle=Transactions%20of%20the%20Royal%20Society%20of%20Tropical%20Medicine%20and%20Hygiene&rft.au=Malenga,%20Grace&rft.date=2009-04&rft.volume=103&rft.issue=1&rft.spage=S15&rft.epage=S18&rft.pages=S15-S18&rft.issn=0035-9203&rft.eissn=1878-3503&rft_id=info:doi/10.1016/j.trstmh.2009.02.003&rft_dat=%3Cproquest_cross%3E733324382%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733324382&rft_id=info:pmid/19285699&rft_els_id=S0035920309000443&rfr_iscdi=true |